SuperworthCytek Biosciences EPS CTKB
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.62
- Latest quarter, Q2 FY26
- −$0.09
- Fiscal year 2025
- −$0.51
Cytek Biosciences' earnings per share was −$0.62 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.09.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.51 | n/a |
| FY2024 | −$0.05 | n/a |
| FY2023 | −$0.09 | −550% |
| FY2022 | $0.02 | n/a |
| FY2021 | $0.00 | −100% |
| FY2020 | $0.11 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.09 | n/a | −$0.62 | |
| Q1 FY26 | −$0.15 | n/a | −$0.57 | |
| Q4 FY25 | −$0.34 | −586% | −$0.51 | |
| Q3 FY25 | −$0.04 | −500% | −$0.10 | |
| Q2 FY25 | −$0.04 | n/a | −$0.05 | |
| Q1 FY25 | −$0.09 | n/a | −$0.09 | |
| Q4 FY24 | $0.07 | +75% | −$0.05 | |
| Q3 FY24 | $0.01 | n/a | −$0.08 | |
| Q2 FY24 | −$0.08 | n/a | −$0.14 | |
| Q1 FY24 | −$0.05 | n/a | −$0.09 | |
| Q4 FY23 | $0.04 | +33% | −$0.09 | |
| Q3 FY23 | −$0.05 | −600% | −$0.10 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Cytek Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CTKBCytek Biosciences | −$0.62 | |
| NRCNRC Health | $0.25 | −67% a year |
| CDNACareDx | $2.07 | +116% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| BLLNBillionToOne | $0.65 | |
| ICCCImmucell | $0.08 | −58% a year |
| LNTHLantheus | $4.13 | +10% a year |
| Peer median | $1.02 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cytek Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.